Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Parasitol Res ; 123(7): 286, 2024 Jul 24.
Artigo em Inglês | MEDLINE | ID: mdl-39046555

RESUMO

Despite being the initial choice for treating toxoplasmosis, sulfadiazine and pyrimethamine have limited effectiveness in eliminating the infection and were linked to a variety of adverse effects. Therefore, the search for new effective therapeutic strategies against toxoplasmosis is still required. The current work is the first research to assess the efficacy of spiramycin-loaded maltodextrin nanoparticles (SPM-loaded MNPs) as a novel alternative drug therapy against toxoplasmosis in a murine model. Fifty laboratory-bred Swiss albino mice were divided into five groups: normal control group (GI, n = 10), positive control group (GII, n = 10), orally treated with spiramycin (SPM) alone (GIII, n = 10), intranasal treated with SPM-loaded MNPs (GIV, n = 10), and orally treated with SPM-loaded MNPs (GV, n = 10). Cysts of Toxoplasma gondii ME-49 strain were used to infect the mice. Tested drugs were administered 2 months after the infection. Drug efficacy was assessed by counting brain cysts, histopathological examination, and measures of serum CD19 by flow cytometer. The orally treated group with SPM-loaded MNPs (GV) showed a marked reduction of brain cyst count (88.7%), histopathological improvement changes, and an increasing mean level of CD19 (80.2%) with significant differences. SPM-loaded MNPs showed potent therapeutic effects against chronic toxoplasmosis. Further research should be conducted to assess it in the treatment of human toxoplasmosis, especially during pregnancy.


Assuntos
Modelos Animais de Doenças , Nanopartículas , Polissacarídeos , Espiramicina , Toxoplasmose Animal , Animais , Espiramicina/uso terapêutico , Espiramicina/administração & dosagem , Camundongos , Polissacarídeos/administração & dosagem , Polissacarídeos/uso terapêutico , Polissacarídeos/farmacologia , Nanopartículas/química , Toxoplasmose Animal/tratamento farmacológico , Toxoplasma/efeitos dos fármacos , Feminino , Encéfalo/parasitologia , Encéfalo/patologia , Antiprotozoários/administração & dosagem , Antiprotozoários/uso terapêutico , Toxoplasmose/tratamento farmacológico , Toxoplasmose/parasitologia , Portadores de Fármacos
2.
J Immunoassay Immunochem ; 45(3): 210-232, 2024 May 03.
Artigo em Inglês | MEDLINE | ID: mdl-38808600

RESUMO

BACKGROUND: Leptin plays a role in regulating energy balance, immunity, and inflammation. Studies suggest higher leptin levels might be associated with various autoimmune diseases. Most of them were in adult. To our knowledge, our study is one of the few that describe serum leptin level and leptin gene polymorphism in children with autoimmune hepatitis (AIH). OBJECTIVE: Our study aims to explore the association between serum leptin level and genetic variations in leptin gene with the likelihood of AIH in children. PATIENTS AND METHODS: Thirty-one children with AIH and 29 healthy children serving as a control group were included. Serum leptin levels were measured by ELISA assays. Leptin rs2167270 genotyping was done using the real time-PCR. The relationship of serum leptin level and leptin gene polymorphism with patients' data was studied. Patients follow up to assess treatment response. RESULTS: Children with AIH had significantly higher levels of leptin compared to healthy controls. GG genotype was significantly more prevalent in the AIH group compared to controls. CONCLUSION: High serum leptin levels and leptin gene polymorphism may play a role in AIH development. It is worthy to recognize if leptin can serve as diagnostic and/or therapeutic target in AIH in children.


Assuntos
Hepatite Autoimune , Leptina , Polimorfismo Genético , Humanos , Leptina/sangue , Leptina/genética , Hepatite Autoimune/genética , Hepatite Autoimune/sangue , Criança , Feminino , Masculino , Pré-Escolar , Adolescente , Genótipo
3.
PLoS One ; 17(10): e0269864, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36201485

RESUMO

Till now the exact mechanism and effect of biogenic silver nanoparticles on fungus is an indefinable question. To focus on this issue, the first time we prepared hydrothermal assisted thyme coated silver nanoparticles (T/AgNPs) and their toxic effect on Candida isolates were determined. The role of thyme (Thymus Vulgaris) in the reduction of silver ions and stabilization of T/AgNPs was estimated by Fourier transforms infrared spectroscopy, structure and size of present silver nanoparticles were detected via atomic force microscopy as well as high-resolution transmission electron microscopy. The biological activity of T/AgNPs was observed against Candida isolates from COVID-19 Patients. Testing of virulence of Candida species using Multiplex PCR. T/AgNPs proved highly effective against Candida albicans, Candida kruzei, Candida glabrata and MIC values ranging from 156.25 to 1,250 µg/mL and MFC values ranging from 312.5 to 5,000 µg/mL. The structural and morphological modifications due to T/AgNPs on Candida albicans were detected by TEM. It was highly observed that when Candida albicans cells were subjected to 50 and 100 µg/mL T/AgNPs, a remarkable change in the cell wall and cell membrane was observed.


Assuntos
COVID-19 , Nanopartículas Metálicas , Antibacterianos/farmacologia , Antifúngicos/química , Antifúngicos/farmacologia , Candida , Candida albicans , Humanos , Nanopartículas Metálicas/química , Testes de Sensibilidade Microbiana , Prata/química
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA